Mikhail Leonidovich Zubkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mikhail Leonidovich Zubkin has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Evgeny Vladimirovich Kryukov
Military Medical Academy
11 shared publications - Valeriy I. Chervinko
G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology; Moscow Clinical Research Center «Hospital No. 52»; Branch of the S.M. Kirov Military Medical Academy
11 shared publications - Nadiya F. Frolova
Moscow Clinical Research Center «Hospital No. 52»; Russian University of Medicine of the Ministry of Health of the Russian Federation
8 shared publications - Irina G. Kim
Gabrichevsky Research Institute for Epidemiology and Microbiology; Moscow Clinical Research Center, Hospital No. 52
7 shared publications N.F. Frolova
5 shared publicationsV G Novozhenov
5 shared publications
Latest Publications
- 25 November 2026
- Published by ECO-Vector LLC (Publications) in Bulletin of the Russian Military Medical Academy
- Vol. 28 (4) , 603-616
Pathogenetic relationship of intestinal microbiota and microbial metabolome with chronic kidney diseases
The modern concept of the “pathogenetic intestine–kidney axis” reflects the connection between the state of the gut microbiome and the development of chronic kidney disease (CKD). Intestinal dysbiosis, caused by various factors, manifests itself as a change in the quantitative and qualitative composition of the microflora, with disruption of production of its metabolites, which are involved in regulating important metabolic and energy processes in the body. Among the most significant of these are short-chain fatty acids (SCFAs), which are formed as a result of bacterial fermentation of indigestible dietary fiber. The effects mediated by SCFAs have not only a local but also a systemic impact. By affecting the permeability of the intestinal mucosa and its peristalsis, the secretion of intestinal hormones, immune activity, and other regulatory mechanisms—including the maintenance of blood pressure—SCFAs ensure the normal functioning of individual organs and systems. In CKD, disruption of the intestinal microbiocenosis is associated with a decrease in the diversity of microorganisms, including commensal ones, which leads to a reduction in the production of key SCFAs and causes disruptions in lipid and carbohydrate metabolism, immune regulation, and the development of inflammatory processes. Against this backdrop, in patients suffering from CKD, as kidney function declines, there is an accumulation of other products of bacterial metabolism, such as indole derivatives, phenols, and others, which, due to their toxic effect, contribute not only to further kidney damage but also to the accelerated development of atherosclerosis and the emergence of cardiovascular complications. The review analyzes and systematizes the results of studies conducted by domestic and foreign authors on the state of the gut microbiome, the spectrum of SCFAs, and other metabolites in patients suffering from CKD, since this problem is relevant not only in terms of clarifying the mechanisms of pathogenesis of this condition but also in assessing the potential of therapeutic approaches aimed at slowing the progression of renal function loss by restoring the normal composition of the gut microbiota.
- 25 November 2026
- Published by ECO-Vector LLC (Publications) in Bulletin of the Russian Military Medical Academy
- Vol. 28 (4) , 603-616
Pathogenetic relationship of intestinal microbiota and microbial metabolome with chronic kidney diseases
The modern concept of the “pathogenetic intestine–kidney axis” reflects the connection between the state of the gut microbiome and the development of chronic kidney disease (CKD). Intestinal dysbiosis, caused by various factors, manifests itself as a change in the quantitative and qualitative composition of the microflora, with disruption of production of its metabolites, which are involved in regulating important metabolic and energy processes in the body. Among the most significant of these are short-chain fatty acids (SCFAs), which are formed as a result of bacterial fermentation of indigestible dietary fiber. The effects mediated by SCFAs have not only a local but also a systemic impact. By affecting the permeability of the intestinal mucosa and its peristalsis, the secretion of intestinal hormones, immune activity, and other regulatory mechanisms—including the maintenance of blood pressure—SCFAs ensure the normal functioning of individual organs and systems. In CKD, disruption of the intestinal microbiocenosis is associated with a decrease in the diversity of microorganisms, including commensal ones, which leads to a reduction in the production of key SCFAs and causes disruptions in lipid and carbohydrate metabolism, immune regulation, and the development of inflammatory processes. Against this backdrop, in patients suffering from CKD, as kidney function declines, there is an accumulation of other products of bacterial metabolism, such as indole derivatives, phenols, and others, which, due to their toxic effect, contribute not only to further kidney damage but also to the accelerated development of atherosclerosis and the emergence of cardiovascular complications. The review analyzes and systematizes the results of studies conducted by domestic and foreign authors on the state of the gut microbiome, the spectrum of SCFAs, and other metabolites in patients suffering from CKD, since this problem is relevant not only in terms of clarifying the mechanisms of pathogenesis of this condition but also in assessing the potential of therapeutic approaches aimed at slowing the progression of renal function loss by restoring the normal composition of the gut microbiota.
- Open Access
- 26 September 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (3) , 325-342
Transformation of approaches to immunosuppressive therapy of IgA nephropathy: from systemic non‑specific to targeted drugs (Part 1)
IgA nephropathy (IgAN) is the most common primary chronic glomerulonephritis worldwide and a major cause of kidney failure requiring kidney replacement therapy. Current evidence indicates that its prognosis is considerably worse than previously assumed, while the proteinuria threshold associated with unfavorable outcome has decreased from 1.0 to 0.5 g/day. Until recently, high-dose systemic glucocorticosteroids, which can cause a wide range of complications, were virtually the only effective treatment. Improved understanding of the mechanisms underlying the development and progression of IgAN has led to new therapeutic approaches. Nefecone, iptacopan, and sibeprenlimab have been approved for clinical use, although the strength of the supporting evidence and their regulatory status may vary. These agents have different mechanisms of action and target distinct components of the pathogenic cascade, including the production of galactose-deficient IgA1 (GdIgA1) and activation of the complement system. GdIgA1acts as an autoantigen promoting the formation of nephritogenic immune complexes and subsequent glomerular inflammation. Nefecone, a targeted-release formulation of budesonide, is thought to modulate B-cell activity and reduce GdIgA1 production in the distal small intestine, where gut-associated lymphoid tissue is concentrated. Sibeprenlimab is a humanized monoclonal antibody that inhibits APRIL (proliferation-inducing ligand), thereby preventing its interaction with receptors on the surface of B cells and, particularly, plasma cells. Iptacopane is a selective proximal inhibitor of factor B, a key protein involved in activation of the alternative complement pathway. Randomized controlled trials, as well as real-world studies of some agents, have demonstrated their efficacy and safety. Fifteen months after completion of Nephecone treatment, proteinuria remained approximately 40% lower than in patients who had received placebo. By this time, the reduction in estimated glomerular filtration rate (eGFR) was 2.47 mL/min/1.73 m 2 in the Nephecone group compared with 7.52 mL/min/1.73 m 2 in the control group, p<0.0001. This literature review examined the evolution of therapeutic approaches to IgAN, from the period of the predominance of systemic glucocorticosteroid therapy to the emergence of targeted treatments. Part 1 discusses controversies surrounding corticosteroid therapy and reviews clinical studies evaluating Nefekon. Part 2 will examine promising classes of targeted therapies.
- 26 September 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (3) , 325-342
Open AccessTransformation of approaches to immunosuppressive therapy of IgA nephropathy: from systemic non‑specific to targeted drugs (Part 1)
IgA nephropathy (IgAN) is the most common primary chronic glomerulonephritis worldwide and a major cause of kidney failure requiring kidney replacement therapy. Current evidence indicates that its prognosis is considerably worse than previously assumed, while the proteinuria threshold associated with unfavorable outcome has decreased from 1.0 to 0.5 g/day. Until recently, high-dose systemic glucocorticosteroids, which can cause a wide range of complications, were virtually the only effective treatment. Improved understanding of the mechanisms underlying the development and progression of IgAN has led to new therapeutic approaches. Nefecone, iptacopan, and sibeprenlimab have been approved for clinical use, although the strength of the supporting evidence and their regulatory status may vary. These agents have different mechanisms of action and target distinct components of the pathogenic cascade, including the production of galactose-deficient IgA1 (GdIgA1) and activation of the complement system. GdIgA1acts as an autoantigen promoting the formation of nephritogenic immune complexes and subsequent glomerular inflammation. Nefecone, a targeted-release formulation of budesonide, is thought to modulate B-cell activity and reduce GdIgA1 production in the distal small intestine, where gut-associated lymphoid tissue is concentrated. Sibeprenlimab is a humanized monoclonal antibody that inhibits APRIL (proliferation-inducing ligand), thereby preventing its interaction with receptors on the surface of B cells and, particularly, plasma cells. Iptacopane is a selective proximal inhibitor of factor B, a key protein involved in activation of the alternative complement pathway. Randomized controlled trials, as well as real-world studies of some agents, have demonstrated their efficacy and safety. Fifteen months after completion of Nephecone treatment, proteinuria remained approximately 40% lower than in patients who had received placebo. By this time, the reduction in estimated glomerular filtration rate (eGFR) was 2.47 mL/min/1.73 m 2 in the Nephecone group compared with 7.52 mL/min/1.73 m 2 in the control group, p<0.0001. This literature review examined the evolution of therapeutic approaches to IgAN, from the period of the predominance of systemic glucocorticosteroid therapy to the emergence of targeted treatments. Part 1 discusses controversies surrounding corticosteroid therapy and reviews clinical studies evaluating Nefekon. Part 2 will examine promising classes of targeted therapies.
- 29 June 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Intestinal microbiota and its metabolites in IGA nephropathy (A literature review)
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis, diagnosed by the presence of dominant immunoglobulin A deposits in the mesangial matrix of the renal glomeruli. Overproduction of galactose-deficient IgA1, associated with lymphoid tissue of the intestinal mucosa, plays a central role in the disease pathogenesis. The state of the intestinal microbiota, as a major source of IgA1 production, is an important factor of shaping immune response diverse antigenic stimuli. Mucosal hyperreactivity, according to numerous studies, is crucial not only in the development but also in the progression of IgAN. The widespread introduction of metagenomic DNA sequencing has demonstrated reduced microbial diversity of the intestinal flora in patients with IgAN compared with the healthy individuals. Another important finding is the identification of genomic loci associated with impaired permeability of the intestinal mucosa and the increased susceptibility to inflammatory diseases in IgAN patients. In addition, a relationship has been reported the genetic predisposition to IgAN, which is believed to involve multilocus interaction of risk alleles, and the composition of the microbiota. In patients with IgAN, a direct correlation was observed between the abundance of specific bacterial families including Actinobacteriaceae, Ruminococcaceae and Bacteroidaceae, and clinical and laboratory parameters such as proteinuria, microhematuria and glomerular filtration rate. In intestinal dysbiosis, the production of key bacterial metabolites, particularly short-chain fatty acids (SCFA) are reduced. These metabolites regulate intestinal barrier permeability, immune response intensity, and antioxidant activity among other processes that may influence the course of the IgAN. Comprehensive analysis of the intestinal microbiome, including quantitative assessment of specific bacterial species and their metabolites, represents a promising direction for further research and may facilitate the development personalized therapeutic strategies for patients with IgAN.
- 29 June 2026
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 28 (2)
Intestinal microbiota and its metabolites in IGA nephropathy (A literature review)
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis, diagnosed by the presence of dominant immunoglobulin A deposits in the mesangial matrix of the renal glomeruli. Overproduction of galactose-deficient IgA1, associated with lymphoid tissue of the intestinal mucosa, plays a central role in the disease pathogenesis. The state of the intestinal microbiota, as a major source of IgA1 production, is an important factor of shaping immune response diverse antigenic stimuli. Mucosal hyperreactivity, according to numerous studies, is crucial not only in the development but also in the progression of IgAN. The widespread introduction of metagenomic DNA sequencing has demonstrated reduced microbial diversity of the intestinal flora in patients with IgAN compared with the healthy individuals. Another important finding is the identification of genomic loci associated with impaired permeability of the intestinal mucosa and the increased susceptibility to inflammatory diseases in IgAN patients. In addition, a relationship has been reported the genetic predisposition to IgAN, which is believed to involve multilocus interaction of risk alleles, and the composition of the microbiota. In patients with IgAN, a direct correlation was observed between the abundance of specific bacterial families including Actinobacteriaceae, Ruminococcaceae and Bacteroidaceae, and clinical and laboratory parameters such as proteinuria, microhematuria and glomerular filtration rate. In intestinal dysbiosis, the production of key bacterial metabolites, particularly short-chain fatty acids (SCFA) are reduced. These metabolites regulate intestinal barrier permeability, immune response intensity, and antioxidant activity among other processes that may influence the course of the IgAN. Comprehensive analysis of the intestinal microbiome, including quantitative assessment of specific bacterial species and their metabolites, represents a promising direction for further research and may facilitate the development personalized therapeutic strategies for patients with IgAN.
- 20 December 2025
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 30 (3) , 157-167
COVID-19 in Moscow patients on peritoneal dialysis: clinical phenotypes
BACKGROUND: The COVID-19 pandemic has greatly altered the management of patients with chronic conditions, including those receiving renal replacement therapy (hemodialysis and peritoneal dialysis) for end-stage renal disease. AIM: This study aimed to identify the clinical phenotypes of patients with peritoneal dialysis and COVID-19, determine the risk factors for adverse outcomes (including death), and evaluate their impact on the progression of end-stage renal disease. METHODS: The work presents a retrospective analysis of the clinical data of patients on peritoneal dialysis diagnosed with COVID-19 and hospitalized at Moscow City Clinical Hospital No. 52 between March 2020 and July 2023. The most frequently observed factors in adverse and fatal cases were assessed. Agglomerative clustering identified three distinct phenotypes in patients with COVID-19 and peritoneal dialysis, which differed in clinical characteristics and associated outcomes. RESULTS: A total of 149 patients undergoing peritoneal dialysis for end-stage renal disease were hospitalized with a diagnosis of COVID-19. Of those, 38 deaths (25.5%) were reported. Deaths were associated with longer durations of renal replacement therapy, higher levels of C-reactive protein, lactate dehydrogenase, and procalcitonin, lower potassium levels at admission, and lower lymphocyte levels during hospitalization. Agglomerative clustering identified three phenotypes in patients with different outcomes. The mortality rate was 2.6% in patients with phenotype 1, 32.4% in patients with phenotype 2, and 64.1% in patients with phenotype 3. Patients with phenotype 3 (the least favorable) were older and had a higher comorbidity index. They had also received renal replacement therapy for a longer period and initially suffered from severe COVID-19 pneumonia. Patients with phenotypes 1 and 2 did not differ in terms of age or comorbidities. However, patients with phenotype 2 had more severe baseline lung lesions, as determined by computed tomography, and higher levels of systemic inflammation markers (C-reactive protein, lactate dehydrogenase, procalcitonin, and ferritin). CONCLUSION: By predicting the progression of the COVID-19 in patients on peritoneal dialysis, we can distinguish three phenotypes characterized by differences in treatment duration, levels of inflammation markers (C-reactive protein and lactate dehydrogenase), and severity of pneumonia. These findings support the need for early risk stratification and multicenter studies to optimize clinical decisions.
- 20 December 2025
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 30 (3) , 157-167
COVID-19 in Moscow patients on peritoneal dialysis: clinical phenotypes
BACKGROUND: The COVID-19 pandemic has greatly altered the management of patients with chronic conditions, including those receiving renal replacement therapy (hemodialysis and peritoneal dialysis) for end-stage renal disease. AIM: This study aimed to identify the clinical phenotypes of patients with peritoneal dialysis and COVID-19, determine the risk factors for adverse outcomes (including death), and evaluate their impact on the progression of end-stage renal disease. METHODS: The work presents a retrospective analysis of the clinical data of patients on peritoneal dialysis diagnosed with COVID-19 and hospitalized at Moscow City Clinical Hospital No. 52 between March 2020 and July 2023. The most frequently observed factors in adverse and fatal cases were assessed. Agglomerative clustering identified three distinct phenotypes in patients with COVID-19 and peritoneal dialysis, which differed in clinical characteristics and associated outcomes. RESULTS: A total of 149 patients undergoing peritoneal dialysis for end-stage renal disease were hospitalized with a diagnosis of COVID-19. Of those, 38 deaths (25.5%) were reported. Deaths were associated with longer durations of renal replacement therapy, higher levels of C-reactive protein, lactate dehydrogenase, and procalcitonin, lower potassium levels at admission, and lower lymphocyte levels during hospitalization. Agglomerative clustering identified three phenotypes in patients with different outcomes. The mortality rate was 2.6% in patients with phenotype 1, 32.4% in patients with phenotype 2, and 64.1% in patients with phenotype 3. Patients with phenotype 3 (the least favorable) were older and had a higher comorbidity index. They had also received renal replacement therapy for a longer period and initially suffered from severe COVID-19 pneumonia. Patients with phenotypes 1 and 2 did not differ in terms of age or comorbidities. However, patients with phenotype 2 had more severe baseline lung lesions, as determined by computed tomography, and higher levels of systemic inflammation markers (C-reactive protein, lactate dehydrogenase, procalcitonin, and ferritin). CONCLUSION: By predicting the progression of the COVID-19 in patients on peritoneal dialysis, we can distinguish three phenotypes characterized by differences in treatment duration, levels of inflammation markers (C-reactive protein and lactate dehydrogenase), and severity of pneumonia. These findings support the need for early risk stratification and multicenter studies to optimize clinical decisions.
- Open Access
- 4 October 2025
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 27 (3) , 242-257
IgA nephropathy: clinical course characteristics and prognosis
IgA nephropathy (IgAN), first described in 1968, is the most common primary glomerulonephritis worldwide. The prevalence of the disease is highest in Asia compared with Europe and North America, with the possible underdiagnosis in regions such as Africa.Typically, debuting in young patients, IgAN is one of the major causes of the development of end-stage chronic kidney disease, which requires the use of renal replacement therapy. However, recent studies have shown a rising incidence among older individuals, often with more severe outcomes.The time course and prognosis of IgAN remain difficult to predict due to the pronounced polymorphism of clinical manifestations and morphological features, apparently reflecting a wide range of possible etiopathogenesis mechanisms. This literature review discusses current approaches to evaluating clinical symptoms and biomarkers in relation to pathomorphological features and disease prognosis. Traditionally, severe proteinuria has been regarded as the only reliable predictor of poor outcomes and the main indication for active treatment. However, recently evidence highlights the prognostic significance of proteinuria of any level, including persistent microhematuria, suggesting the need to reconsider current therapeutic paradigm. Two long-standing debates over the prognostic role of macrohematuria also remain unresolves. In addition, the review addresses the prognostic value of nephrotic syndrome depending on specific histological patterns, such as IgAN with minimal change disease or endocapillary proliferation. Based on published data, clinical variants of IgAN and their associations with disease outcomes are analyzed. The first results of cluster analysis, which have identified distinct disease phenotypes with differing risks of progression and treatment response, are also presented.
- 4 October 2025
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 27 (3) , 242-257
Open AccessIgA nephropathy: clinical course characteristics and prognosis
IgA nephropathy (IgAN), first described in 1968, is the most common primary glomerulonephritis worldwide. The prevalence of the disease is highest in Asia compared with Europe and North America, with the possible underdiagnosis in regions such as Africa.Typically, debuting in young patients, IgAN is one of the major causes of the development of end-stage chronic kidney disease, which requires the use of renal replacement therapy. However, recent studies have shown a rising incidence among older individuals, often with more severe outcomes.The time course and prognosis of IgAN remain difficult to predict due to the pronounced polymorphism of clinical manifestations and morphological features, apparently reflecting a wide range of possible etiopathogenesis mechanisms. This literature review discusses current approaches to evaluating clinical symptoms and biomarkers in relation to pathomorphological features and disease prognosis. Traditionally, severe proteinuria has been regarded as the only reliable predictor of poor outcomes and the main indication for active treatment. However, recently evidence highlights the prognostic significance of proteinuria of any level, including persistent microhematuria, suggesting the need to reconsider current therapeutic paradigm. Two long-standing debates over the prognostic role of macrohematuria also remain unresolves. In addition, the review addresses the prognostic value of nephrotic syndrome depending on specific histological patterns, such as IgAN with minimal change disease or endocapillary proliferation. Based on published data, clinical variants of IgAN and their associations with disease outcomes are analyzed. The first results of cluster analysis, which have identified distinct disease phenotypes with differing risks of progression and treatment response, are also presented.
- 8 June 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (2) , 137-145
Mixed cryoglobulinemia associated with chronic HCV infection: problems of diagnosis and treatment
Mixed cryoglobulinemia is the most common extrahepatic manifestation of chronic HCV infection. Objective of the study. To investigate the frequency and diagnostic criteria of mixed cryoglobulinemia (MCG) associated with chronic HCV infection. Material and methods. The study included 83 patients with chronic HCV infection, aged 50.5 ± 12.6 years, of which 37 (44.6%) were men. The presence of cryoglobulins (CG) was examined, the cryocrit value was calculated, and rheumatoid factor (RF), complement component C4, and individual parameters of cellular immunity were determined. The frequency of MCG, its manifest forms, and immunological disorders were assessed, as well as the impact of antiviral therapy. Results. MCG was found in 61.4% of patients. Manifest forms of the disease were more frequently observed in the group of patients with a cryocrit of 1% or higher compared to those with a cryocrit of 0.5–0.99% (p < 0.017). In a multifactorial model, at a threshold cryocrit value of 0.5%, the detection of CG correlated with the duration of HCV infection (p = 0.001), and at a cryocrit value of 1%, it also correlated with a decrease in complement component C4 (p < 0.025). A sustained virological response (SVR) 12 weeks after the completion of therapy with direct-acting antiviral agents (DAAs) was achieved in 100% of patients. Despite the elimination of the virus, 29.4% of patients continued to have cryoglobulinemia. In 80% of patients with cryoglobulinemic vasculitis, immunological disorders persisted after the disappearance of CG. Conclusion. MCG develops in more than half of patients with chronic HCV infection and can be diagnosed with cryocrit values exceeding 0.5%. Early initiation of DAA therapy is a key factor in the prevention of MCG. The development of SVR does not exclude the persistence of MCG and immunological disorders in the early period after antiviral therapy, which necessitates mandatory long-term monitoring of these parameters.
- 8 June 2025
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 103 (2) , 137-145
Mixed cryoglobulinemia associated with chronic HCV infection: problems of diagnosis and treatment
Mixed cryoglobulinemia is the most common extrahepatic manifestation of chronic HCV infection. Objective of the study. To investigate the frequency and diagnostic criteria of mixed cryoglobulinemia (MCG) associated with chronic HCV infection. Material and methods. The study included 83 patients with chronic HCV infection, aged 50.5 ± 12.6 years, of which 37 (44.6%) were men. The presence of cryoglobulins (CG) was examined, the cryocrit value was calculated, and rheumatoid factor (RF), complement component C4, and individual parameters of cellular immunity were determined. The frequency of MCG, its manifest forms, and immunological disorders were assessed, as well as the impact of antiviral therapy. Results. MCG was found in 61.4% of patients. Manifest forms of the disease were more frequently observed in the group of patients with a cryocrit of 1% or higher compared to those with a cryocrit of 0.5–0.99% (p < 0.017). In a multifactorial model, at a threshold cryocrit value of 0.5%, the detection of CG correlated with the duration of HCV infection (p = 0.001), and at a cryocrit value of 1%, it also correlated with a decrease in complement component C4 (p < 0.025). A sustained virological response (SVR) 12 weeks after the completion of therapy with direct-acting antiviral agents (DAAs) was achieved in 100% of patients. Despite the elimination of the virus, 29.4% of patients continued to have cryoglobulinemia. In 80% of patients with cryoglobulinemic vasculitis, immunological disorders persisted after the disappearance of CG. Conclusion. MCG develops in more than half of patients with chronic HCV infection and can be diagnosed with cryocrit values exceeding 0.5%. Early initiation of DAA therapy is a key factor in the prevention of MCG. The development of SVR does not exclude the persistence of MCG and immunological disorders in the early period after antiviral therapy, which necessitates mandatory long-term monitoring of these parameters.
- Open Access
- 20 September 2024
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 26 (3) , 334-349
Analysis of the course and outcomes of COVID-19 at different stages of the pandemic in hemodialysis patients
The purpose of this study was a comparative analysis of the characteristics of the course and outcomes of COVID-19 in HD patients at different stages of the pandemic, focusing on the of the use of immunomodulatory therapy.Materials and methods. The retrospective study included 897 HD patients with COVID-19 (mean age 60.7 years, M 58.5%) who were hospitalized at Moscow City Hospital № 52. Group 1 (n=720) consisted of patients infected between the end of March 2020 and April 2021, group 2 (n=177) included patients hospitalized in May-December 2021. Each of group was divided into 2 subgroups based on treatment approaches. Subgroup 1a (n=231) included patients of the initial period of the pandemic who did not receive adequate immunomodulatory therapy, while Subgroup 1b (n=489) included patients of the late stage, were treated with IL-6 receptor blockers and corticosteroids. In group 2, 108 patients in Subgroup 2a received similar therapy, while 69 patients in Subgroup 2b were treated with neutralizing monoclonal antibodies in the early stages of the disease.Results. Mortality rates in Group 1 and Group 2 was 20.1% and 14.7%, respectively (pvs 5.8%, pConclusions. The use of immunomodulatory drugs imprtoved the effectiveness of COVID-19 treatment in patients with CKD5D. In severe cases, the most favorable outcomes were achieved with a combination of immunobiological drugs, corticosteroids, and TPE. An even more significant reduction in mortality was observed following the introduction of neutralizing monoclonal antibodies into clinical practice. Independent predictors of unfavorable outcome of COVID-19 in HD patients were a high comorbidity index and the progression of CT 1-2 into CT 3-4.
- 20 September 2024
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 26 (3) , 334-349
Open AccessAnalysis of the course and outcomes of COVID-19 at different stages of the pandemic in hemodialysis patients
The purpose of this study was a comparative analysis of the characteristics of the course and outcomes of COVID-19 in HD patients at different stages of the pandemic, focusing on the of the use of immunomodulatory therapy.Materials and methods. The retrospective study included 897 HD patients with COVID-19 (mean age 60.7 years, M 58.5%) who were hospitalized at Moscow City Hospital № 52. Group 1 (n=720) consisted of patients infected between the end of March 2020 and April 2021, group 2 (n=177) included patients hospitalized in May-December 2021. Each of group was divided into 2 subgroups based on treatment approaches. Subgroup 1a (n=231) included patients of the initial period of the pandemic who did not receive adequate immunomodulatory therapy, while Subgroup 1b (n=489) included patients of the late stage, were treated with IL-6 receptor blockers and corticosteroids. In group 2, 108 patients in Subgroup 2a received similar therapy, while 69 patients in Subgroup 2b were treated with neutralizing monoclonal antibodies in the early stages of the disease.Results. Mortality rates in Group 1 and Group 2 was 20.1% and 14.7%, respectively (pvs 5.8%, pConclusions. The use of immunomodulatory drugs imprtoved the effectiveness of COVID-19 treatment in patients with CKD5D. In severe cases, the most favorable outcomes were achieved with a combination of immunobiological drugs, corticosteroids, and TPE. An even more significant reduction in mortality was observed following the introduction of neutralizing monoclonal antibodies into clinical practice. Independent predictors of unfavorable outcome of COVID-19 in HD patients were a high comorbidity index and the progression of CT 1-2 into CT 3-4.
- 1 January 2022
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 11 (4)
The use of neutralizing monoclonal antibodies against SARS-CoV-2 in hemodialysis patients
Применение нейтрализующих моноклональных антител при SARS-CoV-2-инфекции у больных, получающих лечение гемодиализом
- 1 January 2022
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 11 (4)
The use of neutralizing monoclonal antibodies against SARS-CoV-2 in hemodialysis patients
Применение нейтрализующих моноклональных антител при SARS-CoV-2-инфекции у больных, получающих лечение гемодиализом
- 1 January 2022
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 11 (3)
Mixed cryoglobulinemia in chronic hepatitis C: transformation of perceptions in the context of modern antiviral therapy
Смешанная криоглобулинемия при хроническом гепатите С: трансформация представлений в условиях современной противовирусной терапии
- 1 January 2022
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 11 (3)
Mixed cryoglobulinemia in chronic hepatitis C: transformation of perceptions in the context of modern antiviral therapy
Смешанная криоглобулинемия при хроническом гепатите С: трансформация представлений в условиях современной противовирусной терапии
- 1 January 2022
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 24 (2) , 279-291
The use of therapeutic plasma exchange in the severe forms of COVID-19 in patients with renal fаilure
- 1 January 2022
- Published by Russian Dialysis Society in Nephrology and Dialysis
- Vol. 24 (2) , 279-291
The use of therapeutic plasma exchange in the severe forms of COVID-19 in patients with renal fаilure